Horse Health Corporate News : Schering-Plough Acquires Intervet

News reports from Europe are confirming that Schering-Plough is acquiring Organon BioSciences (OBS), the parent company of Intervet, from Akzo Nobel, in a move that could create a new leader in the globalanimal health industry. The deal, said to be worth 11 billion Euros ($14.4bn), was announced on Monday from the Netherlands headquarters of Schering-Plough.

The deal may place Schering-Plough at the top of animal health corporations worldwide by sales.

One of Schering-Plough’s most familiar equine-market products is the anti-inflammatory Banamine. Intervet makes several widely-used vaccines, plus wormers like Panacur and specialty treatments like Regumate.

Read the press release from the Schering-Plough web site here.

CATEGORIES

TAGS

SHARE THIS STORY

Related Posts

edit 2
Antibiotics & your horse: What you should know
Gray horse head in profile on EQ Extra 89 cover
What we’ve learned about PPID
COVER EQ_EXTRA-VOL88
Do right by your retired horse
COVER EQ_EXTRA-VOL87
Tame your horse’s anxiety

NEWSLETTER

"*" indicates required fields

Name*
Country*

Additional Offers

Additional Offers
This field is for validation purposes and should be left unchanged.
Equus Magazine
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.